Shots: The P-II study involves evaluating the iptacopan vs PBO in 112 patients with IgAN. The new interim results of the P- II study in C3G will also be presented […]readmore
Tags : P-II Study
Shots: The P-IIa POC study involves assessing GSK3640254 (GSK’254, qd) in 34 treatment-naïve adults with HIV. The study is divided into 2 parts- in part 1, patients received GSK’254 (10/200mg) […]readmore
Shots: Sanofi will sponsor the clinical trials while MSD will provide KEYTRUDA. Additionally, Sanofi is separately evaluating the activity of THOR-707 in combination with other anti-PD-1 antibodies, including Libtayo (cemiplimab-rwlc) […]readmore
Shots: The first patient has been dosed in a P-II study of TD-0903. The P-II study consists of two parts: the first part will assess the safety, tolerability, and clinical […]readmore
Shots: The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m2 , […]readmore